KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Profit After Tax (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Profit After Tax for 8 consecutive years, with -$42.9 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 58.96% to -$42.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$438.0 million through Dec 2025, up 16.09% year-over-year, with the annual reading at -$438.0 million for FY2025, 16.09% up from the prior year.
  • Profit After Tax hit -$42.9 million in Q4 2025 for Vir Biotechnology, up from -$163.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $525.3 million in Q4 2021 to a low of -$213.7 million in Q3 2024.
  • Historically, Profit After Tax has averaged -$26.5 million across 5 years, with a median of -$107.8 million in 2024.
  • Biggest five-year swings in Profit After Tax: surged 597.17% in 2021 and later tumbled 223.75% in 2022.
  • Year by year, Profit After Tax stood at $525.3 million in 2021, then tumbled by 119.34% to -$101.6 million in 2022, then dropped by 14.14% to -$116.0 million in 2023, then grew by 9.82% to -$104.6 million in 2024, then surged by 58.96% to -$42.9 million in 2025.
  • Business Quant data shows Profit After Tax for VIR at -$42.9 million in Q4 2025, -$163.1 million in Q3 2025, and -$111.0 million in Q2 2025.